Pharmaceutical company Eli Lilly and Company (NYSE: LLY) and Purdue University announced on Friday a significant expansion of their long-standing alliance, with Lilly's planned investment of up to USD250m in the collaboration over the next eight years.

This partnership, which Lilly says has the potential to be the largest ever industry-academic agreement of its kind in the United States, will seek to accelerate innovation at every stage of the pharmaceutical pipeline.

Key goals for the Lilly-Purdue 360 Initiative include discovering and accelerating the delivery of medicines to patients; bridging the gap between laboratory discoveries and clinical applications; creating more resilient, efficient and sustainable supply chains; and deploying innovative, scalable approaches to workforce development. The expanded collaboration is also expected to generate significant economic benefits for Indiana by creating a highly skilled workforce and fostering local innovation.

The earlier agreement, which had been set to expire in 2027, will now extend with four new projects added through 2032. Additionally, it will engage existing joint programmes, such as Lilly Scholars at Purdue and the Lilly and Purdue Research Alliance Center (LPRC). Purdue will make space available for Lilly researchers on-site in West Lafayette. Purdue researchers will collaborate in Lilly facilities in Indianapolis and in Indiana's LEAP Research and Innovation District.

The Lilly-Purdue 360 Initiative supports Purdue's One Health initiative, which aims to advance knowledge and innovation related to animal, human and plant well-being through novel interdisciplinary initiatives and partnerships with industry.